Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
2022; Massachusetts Medical Society; Volume: 386; Issue: 24 Linguagem: Inglês
10.1056/nejmoa2200075
ISSN1533-4406
AutoresJeanne Tie, Joshua D. Cohen, Kamel Lahouel, Serigne Lo, Yuxuan Wang, Suzanne Kosmider, Rachel Wong, Jeremy Shapiro, Margaret Lee, Sam Harris, Adnan Khattak, Matthew Burge, Marion Harris, James Lynam, Louise Nott, Fiona Day, Theresa Hayes, Sue‐Anne McLachlan, Belinda Lee, Janine Ptak, Natalie Silliman, Lisa Dobbyn, Maria Popoli, Ralph H. Hruban, Anne Marie Lennon, Nicholas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Cristian Tomasetti, Peter Gibbs,
Tópico(s)Colorectal Cancer Treatments and Studies
ResumoThe role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood.
Referência(s)